Nikka Jones, Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 12200 E 13 Mile Rd, Warren, MI 48093 Phone: 586-573-1810 |
Raneen Zetouna, NP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 31500 Dequindre Rd, Warren, MI 48092 Phone: 586-939-9500 |
Todd Marshall Roark, NP Nurse Practitioner - Acute Care Medicare: Accepting Medicare Assignments Practice Location: 11800 E 12 Mile Rd, Warren, MI 48093 Phone: 586-573-5402 Fax: 586-573-5580 |
Shormin Akter, MSN, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 24831 Ryan Rd, Warren, MI 48091 Phone: 586-486-5037 |
News Archive
It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.
The hundred trillion bacteria living in an adult human-mostly in the intestines, making up the gut microbiome-have a significant impact on behavior and brain health. The many ways gut bacteria can impact normal brain activity and development, affect sleep and stress responses, play a role in a variety of diseases, and be modified through diet for therapeutic use are described in a comprehensive Review article in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published today in the journal Obstetrics & Gynecology.
Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.
Osteoporosis and periodontitis are common diseases whose sufferers must cope with weakness, injury and reduced function as they lose bone more quickly than it is formed. While the mechanism of bone destruction in these diseases is understood, scientists have had less information about how bone formation is impaired.
› Verified 8 days ago